Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of ML007C-MA in Alzheimer's Disease Psychosis
NCT07459660Phase 2Enrolling by invitation
- Sponsor
- MapLight Therapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ML-007/PAC in Alzheimer's disease (AD), sponsored by MapLight Therapeutics. Primary endpoint: Safety and tolerability of long-term ML-007C-MA administration at 52 weeks. Started Mar 2026; status: enrolling by invitation.
02
Drugs
ML-007/PAC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07459660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459660.